Global Diabetes Devices and Therapeutics Business Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q2 2023 Update

According to the publisher, the global diabetes devices market size is expected to record a CAGR of 9.2% during 2023-2027 to reach US$178.219 billion by 2027, increasing from US$114.973 billion in 2023. Over the last five years, the sector has recorded a CAGR of 10.3% to reach US$104.244 billion in 2022.

Millions of individuals worldwide are impacted by diabetes, a persistent medical condition. Effective management of diabetes plays a critical role in preventing or delaying related complications, including heart disease, kidney disease, blindness, and amputations. Diabetes devices and therapeutics market have evolved significantly over the years, providing people with diabetes with more options to manage their condition effectively. The prevalence of diabetes has been steadily increasing worldwide, largely due to lifestyle changes, including sedentary lifestyles, unhealthy diets, and increasing obesity rates.

• Diabetes continues to be a prevalent global health issue, affecting an estimated 537 million individuals worldwide in 2021, a figure expected to rise to 642 million by 2040, as reported by the International Diabetes Federation (IDF). In 2019, diabetes was responsible for 1.5 million deaths, with 48% of those deaths occurring before the age of 70.
• Additionally, diabetes contributed to an additional 460,000 deaths from kidney disease, and roughly 20% of all cardiovascular deaths. Between 2,000 and 2019, there was a 3% increase in age-standardized mortality rates due to diabetes, with a 13% increase in lower-middle-income countries. However, there was a 22% reduction in the probability of dying from any of the four main non-communicable diseases, including diabetes, globally between the ages of 30 and 70 years during the same period.

Riding the Wave of Innovation: Advancements in Diabetes Management

Effectively managing diabetes is imperative in preventing complications that can significantly impact an individual's health and well-being. Prolonged periods of elevated blood glucose levels can inflict damage to blood vessels, nerves, and organs, consequently resulting in serious health implications, such as heart disease, stroke, kidney disease, eye complications, nerve damage, and the possibility of amputation.

Poorly controlled diabetes can also increase the risk of infections, slow the healing of wounds, and cause other health problems. However, with proper diabetes management, including regular monitoring of blood glucose levels, a healthy diet, regular exercise, and medications such as insulin or oral medications, many of these complications can be prevented or delayed. Hence, collaborating with healthcare providers to devise an individualized diabetes management plan is vital for individuals with diabetes. This plan assists them in attaining optimal blood glucose control and preventing potential complications.

• While Continuous Glucose Monitoring (CGM) devices are useful for managing both types of diabetes, Type 1 Diabetes (T1D) is the more established area for improving glycemic control and reducing hypoglycemia. As technology has become more accessible and cost-effective, healthcare guidelines have recently facilitated the widespread adoption of CGMs.
• The adoption of CGM has also accelerated over this time, with the global Dexcom user base rising from 270,000 users at the end of 2,017 to 1.7 million users at the end of 2022.
• In August 2022, the National Health Service (NHS) in England made CGMs available to all patients with T1D. A decade ago, such an extensive rollout would have been unlikely. The increasing prevalence of diabetes, coupled with technological advancements, has prompted health institutions to advocate for CGM allowances.
• The market for tubeless insulin pumps is expanding quickly due to factors such the rising prevalence of diabetes globally, the increased demand for non-invasive insulin delivery systems, and the advantages of tubeless insulin pumps, including better glycemic control and patient quality of life.
• In 2021, the Bigfoot Unity AI Diabetes Management System by Bigfoot Biomedical has been approved by the FDA for the management of T1D and T2D in patients aged 12 and older.
• Consumables & Supplies for Diabetes is a highly commoditized market. However, businesses like BD and Terumo have been successful in fostering innovation through cutting-edge product design and cutting-edge technology. While BD holds the top spot in syringes and pen needles that use cutting-edge technologies like BD FlowSmart and inventive insulin infusion set, Terumo has used its extensive needle design to minimise the pain associated with injections through its Nanopasspen needles, the thinnest needles in the world.

Light at the End of the Tunnel: New Approaches to Diabetes Control

• Insulin therapy: A few months after losing $15 billion in market cap due to a bogus tweet, Eli Lilly announced a 70% price cut for its most frequently prescribed insulins on March 1, 2023. Soon after, Novo Nordisk announced plans to lower the price of its pre-filled pens and vials. Sanofi has followed suit by slashing pricing for Lantus (insulin glargine), its most popular insulin product, by 78% as a result of the mounting public backlash against price increases.
• Non-insulin therapy: Wanbang Biopharmaceuticals, a Chinese pharmaceutical company, has announced its plans to expand its partnership with Canadian biotech company Sirona Biochem. The two companies have been working together for several years on the development of a non-insulin treatment for diabetes in both humans and animals. Under the terms of the expanded agreement, Wanbang Biopharmaceuticals will have the exclusive global licensing rights to the investigational diabetes treatment. This will allow the company to commercialize the drug in markets around the world, including China, where the prevalence of diabetes is high.
• Significant progress has been made towards the development of a fully closed-loop system since the mid-2000s, which can be attributed to the advancement and commercialization of several sophisticated glucose-sensing and insulin delivery systems. Researchers have shifted their focus towards subcutaneous-subcutaneous closed-loop systems, given the significant technological advancements made with insulin pumps and interstitial glucose-sensing devices.
• The STG-55, and its predecessor the STG-22, are the only fully closed-loop systems currently available in the market. These devices are stationary and require intravenous-intravenous access for glucose sensing and insulin delivery, as opposed to the wearable hybrid technologies that are more prevalent. The STG-55 is currently only approved for use in Japan, and its usage is limited to a maximum of three days in the perioperative setting.
• Results from the 13-week randomised PEDAP trial conducted across three paediatric diabetes centres in the United States indicate that artificial pancreas technology can improve blood glucose control in young children aged between two and five with type 1 diabetes. The National Institutes of Health's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provided funding for the study, and the findings were published in the New England Journal of Medicine.
• In 2022, the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) injectable to help adults with type 2 diabetes to better regulate their blood sugar levels. In clinical investigations, Mounjaro was compared to other diabetic treatments and found to be more effective at lowering blood sugar.
• Although current glucose-lowering drugs have some helpful impacts, morbidity and mortality rates are still significant in diabetic patients. This highlights the need for the development of pharmacotherapeutics that focus on the various metabolic irregularities and pathways associated with morbidity. Certain findings may highlight the constraints of existing diabetic therapies, as they may produce unintended side effects that counteract the potential advantages of glucose-lowering medications.
• Among the various discoveries made in the field of diabetic treatments, the SGLT2 inhibitors have emerged as a promising option with relatively minimal drawbacks. However, additional research is required to validate their safety and effectiveness. While phase-III clinical trials have indicated that vulvovaginal candidiasis and mycotic infections are the most common side effects observed in females, another concern that has been raised is osmotic diuresis. This is due to the increased excretion of glucose in urine that results in higher output of water and solutes, potentially leading to ketoacidosis or acidosis resulting from hyperkalemia and renal insufficiency.
• Despite the potential advantages of SGLT2 inhibitors, their long-term use can be expensive and challenging. Consequently, there is a rising interest in identifying novel drug molecules that can stimulate sirtuins. Among these compounds, resveratrol is considered to be the best-characterized, although it does not directly activate SIRT1. As a result, several analogous molecular structures, such as SRT1,720 and SRT2104, have been developed.

In the future, ongoing research and innovation will play a critical role in revolutionizing diabetes management. Advanced technologies, such as continuous glucose monitoring devices, artificial pancreas systems, and gene therapy, will allow for more personalized and precise treatment options. Novel pharmacotherapeutics and regenerative medicine approaches, including stem cell and islet cell transplantation therapies, will provide new hope for those with severe and complicated diabetes. Additionally, machine learning and big data analytics will help identify new risk factors and biomarkers, leading to earlier and more accurate diagnosis and treatment. As such, the importance of continued investment in research and innovation in diabetes management cannot be overstated, as it will lead to improved quality of life, reduced healthcare costs, and ultimately, the prevention and cure of diabetes.

This report offers a comprehensive evaluation of the present market landscape, focusing on the prospective growth opportunities within the Diabetes Devices and Therapeutics sector. By utilizing a blend of thorough secondary research and primary research methods, in conjunction with a proprietary predictive analytics platform, the publisher's research approach provides impartial business insights and addresses crucial inquiries pertaining to the Diabetes Devices and Therapeutics market.

It aims to provide a comprehensive overview of diabetes devices and therapeutics, highlighting their impact on diabetes management and patient outcomes, and emphasizing the need for ongoing research and innovation in this field. It will discuss the different types of diabetes devices, including blood glucose meters, continuous glucose monitors insulin pumps, and insulin pens, as well as various diabetes therapeutics, including insulin therapy and non-insulin therapy. Investors will be able to explore the advantages and limitations of each device and therapy and discuss the challenges associated with their use. Additionally, it provides a panoramic view to the emerging diabetes devices and technologies and the novel therapeutics that are currently being designed and developed.

This comprehensive report offers an extensive data-driven examination of the emerging prospects within the diabetes devices and therapeutics industry. It presents a detailed overview of market size and projections across multiple segments, including category, diagnosis and monitoring devices, therapeutics, route of administration, type of diabetes, distribution channels, product, and end-users. Furthermore, the report includes expert commentary on significant trends, drivers, strategies, innovations, and regulations pertaining to the Diabetes Devices and Therapeutics market.

This title provides global and regional insights along with data-centric analysis for the following 6 regions and 21 countries:

• Global
• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• France
• Germany
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• Australia
• India
• South Korea
• Latin America
• Brazil
• Argentina
• Colombia
• MEA
• Israel
• South Africa
• Saudi Arabia
• Turkey

Scope

Insights and data in the report have been segmented under the following six modules:

Module 1: Global Diabetes Devices & Therapeutics Investment Landscape

This module provides insights and data related to diabetes devices & therapeutics partnerships and investment (research and development, mergers and acquisitions, product development, commercialization, licensing, and manufacturing) and allows a peek into the futuristic trends of diabetes devices & therapeutics technology investment area.

Module 2: Global Diabetes Devices & Therapeutics Clinical Trial Data Assessment

This module evaluates the data available from clinical trials related to diabetes devices & therapeutics, representing a bird’s eye view of emerging market dynamics and risks in the diabetes devices & therapeutics sector.

Module 3: Global Diabetes Devices & Therapeutics Patent Data Analysis

This module presents an exhaustive study of diabetes devices & therapeutics patent analytics at various levels, including strategic research planning as well as analyzing their potential applications.

Module 4: Competitive Landscape

This module provides detailed information along with a scoring matrix of key companies related to the diabetes devices & therapeutics industry, including their historical performance and the latest developments.

Module 5: Global diabetes devices & therapeutics Market Size and Forecast

This module provides projections on the market's development during the years 2018-2027 after the profound evaluation of market dynamics at the deeper segmentation level. This report also provides an in-depth, data-centric analysis of the global diabetes devices & therapeutics market at regional and country levels:

Diabetes Devices and Therapeutics Market Share by Category

• Diagnosis and Monitoring Devices
• Therapeutics

Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices

• Blood Glucose Monitoring Devices
• Insulin Delivery Devices
• Diabetes Management and Mobile Applications
• Artificial Pancreas Devices

Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices

• Self-Monitoring Blood Glucose Devices
• Continuous Blood Glucose Monitoring Devices
• Test Strips
• Lancets

Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices

• Insulin Pumps
• Insulin Pens
• Insulin Syringes

Diabetes Devices and Therapeutics Market Share by Therapeutics

• Oral Anti-Diabetic Drugs
• Insulin
• Non-Insulin Injectable Drugs
• Combination Drugs

Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs

• Alpha-Glucosidase Inhibitors
• DPP-4 Inhibitors
• SGLT-2 Inhibitors

Diabetes Devices and Therapeutics Market Share by Insulin

• Basal or Long-Acting
• Bolus or Fast-Acting
• Traditional Human Insulin Drugs
• Insulin Biosimilars

Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs

• GLP-1 Receptor Agonists
• Amylin Analogue

Diabetes Devices and Therapeutics Market Share by Combination Drugs

• Combination Insulin
• Oral Combination

Diabetes Devices and Therapeutics Market Share by Route of Administration

• Subcutaneous
• Intravenous
• Others

Diabetes Devices and Therapeutics Market Share by Type of Diabetes

• Type 1 Diabetes
• Type 2 Diabetes

Diabetes Devices and Therapeutics Market Share by Distribution Channels

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Diabetes Devices and Therapeutics Market Share by End User

• Hospitals
• Diabetes Clinics
• Homecare

Diabetes Devices & Therapeutics Market Size By Regions

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Germany
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• Australia
• India
• South Korea
• MEA region
• Israel
• South Africa
• Turkey
• Saudi Arabia
• Latin America
• Brazil
• Argentina
• Colombia

Key Companies Covered

• Abbott
• Eli Lilly and Company
• Sanofi
• Johnson & Johnson
• Roche Diagnostics
• AstraZeneca
• Novo Nordisk
• Tandem Diabetes Care
• Novartis
• Medtronic Plc

Module 6 Regulatory Outlook

This module contains a detailed understanding of the ethical, legal, and social implications of diabetes devices & therapeutics.

Reasons to buy

• Diabetes Devices and Therapeutics Market Dynamics: Understand market opportunities and key trends along with forecast (2023-2027). Understand market dynamics across various segments such as by category, diagnosis and monitoring devices, therapeutics, route of administration, type of diabetes, distribution channels, and end users.
• Competitive Landscape Analysis: Market position and snapshot of key players in the development of diabetes devices and therapeutics. Each profile includes a brief overview of the company, information on its therapeutic pipeline, financial data (where available), the most recent events, and future direction of the market.
• Clinical Trial Analysis: Insights into opportunities across Diabetes Devices and Therapeutics field that have been completed or are still ongoing, using parameters such as trial status, trial registration year, an indication of the target disease, trial phase, patient enrolment, and sponsor/collaborator type.
• Develop Market-Specific Strategies: Identify growth segments based on a thorough analysis of the diabetes devices and therapeutics patents that have been applied for or granted based on the patent type, the issuing agency, and patent offices involved, the Cooperative Patent Classification (CPC) symbols, the firm type, significant industry and non-industry participants (based on many patents), and discrete patent assignees.
• Financial Deals Insights: Get insights into various diabetes devices and therapeutics partnerships that have been developed, including those for research and development (R&D), clinical trials, mergers and acquisitions, product development, commercialization, licencing, and manufacturing. A complete analysis of the various investments made in companies that specialise in developing drugs using diabetes devices and therapeutics technologies.